학술논문
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban
Document Type
Academic Journal
Author
Mapelli, Massimo; Mattavelli, Irene; Salvioni, Elisabetta; Capra, Nicolò; Bonomi, Alice; Cattadori, Gaia; Pezzuto, Beatrice; Campodonico, Jeness; Piotti, Arianna; Nava, Alessandro; Piepoli, Massimo; Magrì, Damiano; Paolillo, Stefania; Corrà, Ugo; Raimondo, Rosa; Lagioia, Rocco; Vignati, Carlo; Badagliacca, Roberto; Perrone Filardi, Pasquale; Senni, Michele; Correale, Michele; Cicoira, Mariantonietta; Metra, Marco; Guazzi, Marco; Limongelli, Giuseppe; Parati, Gianfranco; De Martino, Fabiana; Bandera, Francesco; Bussotti, Maurizio; Re, Federica; Lombardi, Carlo M.; Scardovi, Angela B.; Sciomer, Susanna; Passantino, Andrea; Emdin, Michele; Santolamazza, Caterina; Perna, Enrico; Passino, Claudio; Sinagra, Gianfranco; Agostoni, Piergiuseppe
Source
Journal of Clinical Medicine. December 2023, Vol. 13 Issue 1
Subject
Language
English
ISSN
2077-0383
Abstract
Author(s): Massimo Mapelli [1,2]; Irene Mattavelli [1]; Elisabetta Salvioni [1]; Nicolò Capra [1]; Alice Bonomi [1,2]; Gaia Cattadori (corresponding author) [2,3,*]; Beatrice Pezzuto [1]; Jeness Campodonico [1,2]; Arianna Piotti [1]; [...]
Introduction: Risk stratification in heart failure (HF) is essential for clinical and therapeutic management. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score is a validated prognostic model for assessing cardiovascular risk in HF patients with reduced ejection fraction (HFrEF). From the validation of the score, the prevalence of HF patients treated with direct oral anticoagulants (DOACs), such as edoxaban, for non-valvular atrial fibrillation (NVAF) has been increasing in recent years. This study aims to evaluate the reliability of the MECKI score in HFrEF patients treated with edoxaban for NVAF. Materials and Methods: This study included consecutive outpatients with HF and NVAF treated with edoxaban (n = 83) who underwent a cardiopulmonary exercise test (CPET). They were matched by propensity score with a retrospective group of HFrEF patients with NVAF treated with vitamin K antagonists (VKAs) from the MECKI score registry (n = 844). The study endpoint was the risk of cardiovascular mortality, urgent heart transplantation, or Left Ventricle Assist Device (LVAD) implantation. Results: Edoxaban patients were treated with a more optimized HF therapy and had different clinical characteristics, with a similar MECKI score. After propensity score, 77 patients treated with edoxaban were successfully matched with the MECKI-VKA control cohort. In both groups, MECKI accurately predicted the composite endpoint with similar area under the curves (AUC = 0.757 vs. 0.829 in the MECKI-VKA vs. edoxaban-treated group, respectively, p = 0.452). The two populations’ survival appeared non-significantly different at the 2-year follow-up. Conclusions: this study confirms the prognostic accuracy of the MECKI score in HFrEF patients with NVAF treated with edoxaban, showing improved predictive power compared to VKA-treated patients.
Introduction: Risk stratification in heart failure (HF) is essential for clinical and therapeutic management. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score is a validated prognostic model for assessing cardiovascular risk in HF patients with reduced ejection fraction (HFrEF). From the validation of the score, the prevalence of HF patients treated with direct oral anticoagulants (DOACs), such as edoxaban, for non-valvular atrial fibrillation (NVAF) has been increasing in recent years. This study aims to evaluate the reliability of the MECKI score in HFrEF patients treated with edoxaban for NVAF. Materials and Methods: This study included consecutive outpatients with HF and NVAF treated with edoxaban (n = 83) who underwent a cardiopulmonary exercise test (CPET). They were matched by propensity score with a retrospective group of HFrEF patients with NVAF treated with vitamin K antagonists (VKAs) from the MECKI score registry (n = 844). The study endpoint was the risk of cardiovascular mortality, urgent heart transplantation, or Left Ventricle Assist Device (LVAD) implantation. Results: Edoxaban patients were treated with a more optimized HF therapy and had different clinical characteristics, with a similar MECKI score. After propensity score, 77 patients treated with edoxaban were successfully matched with the MECKI-VKA control cohort. In both groups, MECKI accurately predicted the composite endpoint with similar area under the curves (AUC = 0.757 vs. 0.829 in the MECKI-VKA vs. edoxaban-treated group, respectively, p = 0.452). The two populations’ survival appeared non-significantly different at the 2-year follow-up. Conclusions: this study confirms the prognostic accuracy of the MECKI score in HFrEF patients with NVAF treated with edoxaban, showing improved predictive power compared to VKA-treated patients.